PACIFIC EDGE LIMITED (PEB)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
![](/stocklogo/PEB.jpg)
PEB - PACIFIC EDGE LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.04
Index:
FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.04
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.08
30 Aug |
0.000 OPEN $0.08 |
0.000 HIGH $0.08 |
6 LOW $0.08 |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PGC . PME . RAP . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 22.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 6.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -23.9 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -123.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -42.98 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -42.09 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -37.78 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -42.98 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -48.92 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -24.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 46 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.26 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
![](/images/chart-unavailable.png)
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 1.3 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 5.74 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 12 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 43 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 11 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
PEB STOCK CHART
![](/wp-content/uploads/2020/10/img-side-banner-stock-analysis.jpg)
FNArena News on PEB
1 |
July In Review: Energy And Banks Drive GainsAug 03 2023 - Australia |
2 |
FNArena Corporate Results Monitor – 02-06-2023Jun 02 2023 - Australia |
3 |
Australian Broker Call *Extra* Edition – Jan 25, 2023Jan 25 2023 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Oct 25, 2022Oct 25 2022 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Aug 09, 2022Aug 09 2022 - Daily Market Reports |
Latest Medical Equipment & Devices News
1 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
2 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
3 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
4 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
5 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
6 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
7 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
8 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
9 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
10 |
ResMed Makes A ComebackJan 29 2024 - Australia |